Masimo Price to Free Cash Flow Ratio 2010-2024 | MASI

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

Masimo average price to free cash flow ratio for 2023 was 31.64, a 55.88% increase from 2022.
Masimo average price to free cash flow ratio for 2022 was 71.72, a 8.09% decline from 2021.
Masimo average price to free cash flow ratio for 2021 was 78.03, a 16.47% decline from 2020.

Price to free cash flow ratio can be defined as

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

PE Ratio P/S Ratio Price/Book Ratio Price-FCF Ratio Net Worth

Masimo average price to free cash flow ratio for 2023 was 31.64, a 55.88% increase from 2022.
Masimo average price to free cash flow ratio for 2022 was 71.72, a 8.09% decline from 2021.
Masimo average price to free cash flow ratio for 2021 was 78.03, a 16.47% decline from 2020.

Price to free cash flow ratio can be defined as

Related Stocks
Company Name	Market Cap
Thermo Fisher Scientific (TMO)	$233.2B
Intuitive Surgical (ISRG)	$171.7B
Alcon (ALC)	$47.9B
IQVIA Holdings (IQV)	$43.7B
IDEXX Laboratories (IDXX)	$42.2B
Edwards Lifesciences (EW)	$40.5B
DexCom (DXCM)	$27.6B
STERIS (STE)	$23.8B
SONOVA HOLDING (SONVY)	$21.2B
Waters (WAT)	$19.5B
Hologic (HOLX)	$19B
Sysmex ADR (SSMXY)	$12.6B
Fresenius Medical Care AG KGaA (FMS)	$12.3B
Teleflex (TFX)	$11.4B
Globus Medical (GMED)	$9.4B
Penumbra (PEN)	$7.3B
Glaukos (GKOS)	$6.7B
TransMedics (TMDX)	$5.2B
Integer Holdings (ITGR)	$4.2B
PROCEPT BioRobotics (PRCT)	$4.1B
Tandem Diabetes Care (TNDM)	$2.8B
LivaNova (LIVN)	$2.8B
Veracyte (VCYT)	$2.6B
Inari Medical (NARI)	$2.6B
Elekta AB (EKTAY)	$2.5B
Nihon Kohden (NHNKY)	$2.5B
RxSight (RXST)	$2.1B
Integra LifeSciences Holdings (IART)	$1.3B
Pulse Biosciences (PLSE)	$1.2B
OPKO Health (OPK)	$1.2B